Search

everythinglearnresearchcommunity

for

Search:↓

Early genetic testing and zinc therapy are crucial for managing acrodermatitis enteropathica in infants.

Pediatric patients with dystrophic epidermolysis bullosa face more hospital admissions, procedures, and complications than others.

A new mutation in the FLCN gene linked to Birt-Hogg-Dube syndrome was found, suggesting people with certain lung collapse should be tested for this mutation and screened for kidney and colon cancer.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

Wnt7a helps corneal cells grow and stick together, aiding in repair.

Targeted anticancer therapies often cause skin issues, affecting treatment adherence and quality of life.

Not having enough cystatin M/E protein causes less hair growth and dry skin.

Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.

Ixekizumab has known and some unexpected side effects.

The nanofibers improved cell adhesion and could be used for tissue-engineered blood vessels.

Epidermolysis bullosa in calves was not caused by mutations in the keratin genes bKRT5 and bKRT14.

The new cocrystal KET-PABA is a more effective and safe anti-inflammatory treatment for skin conditions in mice.

The 595-nm pulsed dye laser effectively reduces symptoms of EFFC with minimal side effects.

Certain cancer drugs interact with skin bacteria to cause acne-like rashes.

Genetic testing is crucial for diagnosing and treating acrodermatitis enteropathica effectively.

Diphenyl ethers can potentially reduce excess oil production when applied on the skin, helping treat conditions like acne.

The protein FLCN is involved in cellular cleanup and is regulated by ULK1.

A special dressing called FEA-PCEI can speed up wound healing, reduce scars, and help grow new hair follicles, but only at the right dosage.

A woman with bullous pemphigoid had an allergic reaction to azathioprine, but got better with alternative treatments.

Most Recessive Dystrophic Epidermolysis Bullosa patients with a specific mutation likely have Sephardic ancestry from about 500 years ago.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

S1PR1 helps control inflammation in blood vessel cells by affecting gene activity differently in various cell types and locations.

Sphingosine 1-phosphate affects inflammation and gene expression in different aorta cells.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

CD99 is highly present in certain skin cells and could help treat skin conditions.

Neutrophils are key in causing chronic itch in atopic dermatitis, and blocking CXCR3 could reduce this itch.

A new molecule was found to be a safe and effective skin lightener and anti-aging product.